44 results
IDSA Recommendations for empirical antimicrobial therapy for purulent meningitis based on patient age and specific predisposing
IDSA Recommendations ... antimicrobial therapy ... condition #IDSA ... InfectiousDiseases #Pharmacology ... #Management
Recommendations for specific antimicrobial therapy in bacterial meningitis based on isolated pathogen and susceptibility testing.

#IDSA #Meningitis
antimicrobial therapy ... #IDSA #Meningitis ... InfectiousDiseases #Pharmacology ... #Management
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
IDSA - Prophylaxis ... Infections #OIs #HIVAIDS ... #IDSA #management ... #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
IDSA - Prophylaxis ... Infections #OIs #HIVAIDS ... #IDSA #management ... #pharmacology
Acute Coronary Syndrome - Management Algorithm
 • STEMI
 • NSTEMI (Troponin Positive) / Unstable Angina (UA,
Coronary Syndrome - Management ... : • PCI • Fibrinolysis ... Immediate Medical Therapy ... Optimize Medical Therapy ... #Algorithm #cardiology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
IDSA Recommendations ... Penicilliosis #IDSA ... Prevention #Treatment #management ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
IDSA Recommendations ... candida #mucosal #IDSA ... Prevention #Treatment #management ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
IDSA Recommendations ... Enteric #Bacterial #IDSA ... Prevention #Treatment #management ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Treatment Recommendations for Cryptococcal Meningoencephalitis in Human Immunodeficiency Virus Infected Individuals
Induction therapy:
 • AmBd (0.7–1.0
IDSA Treatment Recommendations ... for induction therapy ... Meningoencephalitis #IDSA ... #Treatment #management ... #cryptococcus #HIVAIDS
Summary of characteristics of Antianginal Drugs

DRUG CLASS, ADVERSE EFFECTS 
 AND DRUG 
INTERACTIONS 

#Antianginal #Medications #Cardiology
#Medications #Cardiology ... #Pharmacology # ... Management #Therapy